Literature DB >> 9395356

Increased prevalence of infectious diseases and other adverse outcomes in human T lymphotropic virus types I- and II-infected blood donors. Retrovirus Epidemiology Donor Study (REDS) Study Group.

E L Murphy1, S A Glynn, J Fridey, R A Sacher, J W Smith, D J Wright, B Newman, J W Gibble, D I Ameti, C C Nass, G B Schreiber, G J Nemo.   

Abstract

Disease associations of human T lymphotropic virus types I and II (HTLV-I and -II) infection were studied in 154 HTLV-I-infected, 387 HTLV-II-infected, and 799 uninfected blood donors. Adjusted odds ratios (ORs) and 99% confidence intervals (CIs) were derived from logistic regression models controlling for demographics and relevant confounders. All subjects were human immunodeficiency virus type 1-seronegative. HTLV-II was significantly associated with a history of pneumonia (OR, 2.6; 99% CI, 1.2-5.3), minor fungal infection (OR, 2.9; 99% CI, 1.2-7.1), and bladder or kidney infection (OR, 1.6; 99% CI, 1.0-2.5) within the past 5 years and with a lifetime history of tuberculosis (OR, 3.9; 99% CI, 1.3-11.6) and arthritis (OR, 1.8; 99% CI, 1.2-2.9). Lymphadenopathy (> or =1 cm) was associated with both HTLV-I (OR, 6.6; 99% CI, 2.2-19.2) and HTLV-II (OR, 2.8; 99% CI, 1.1-7.1) infection, although no case of adult T cell leukemia/lymphoma was diagnosed. Urinary urgency and gait disturbance were associated with both viruses. This new finding of increased prevalence of a variety of infections in HTLV-II-positive donors suggests immunologic impairment.

Entities:  

Mesh:

Year:  1997        PMID: 9395356     DOI: 10.1086/514143

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  27 in total

1.  HTLV-2 APH-2 expression is correlated with proviral load but APH-2 does not promote lymphocytosis.

Authors:  Estelle Douceron; Zhanna Kaidarova; Paola Miyazato; Masao Matsuoka; Edward L Murphy; Renaud Mahieux
Journal:  J Infect Dis       Date:  2011-11-07       Impact factor: 5.226

2.  Increased all-cause and cancer mortality in HTLV-II infection.

Authors:  Hope H Biswas; Zhanna Kaidarova; George Garratty; Joan W Gibble; Bruce H Newman; James W Smith; Alyssa Ziman; Joy L Fridey; Ronald A Sacher; Edward L Murphy
Journal:  J Acquir Immune Defic Syndr       Date:  2010-07       Impact factor: 3.731

3.  Human T cell leukemia virus type 1 infection drives spontaneous proliferation of natural killer cells.

Authors:  Philip J Norris; Dale F Hirschkorn; Deborah A DeVita; Tzong-Hae Lee; Edward L Murphy
Journal:  Virulence       Date:  2010 Jan-Feb       Impact factor: 5.882

4.  A tax on luxury: HTLV-I infection of CD4+CD25+ Tregs.

Authors:  Robert S Fujinami
Journal:  J Clin Invest       Date:  2005-05       Impact factor: 14.808

5.  Enhanced inhibition of lymphocyte activation by Mycobacterium avium complex in human T lymphotrophic virus type I carriers.

Authors:  W Matsuyama; R Kubota; T Hamasaki; A Mizoguchi; F Iwami; J Wakimoto; M Kawabata; M Osame
Journal:  Thorax       Date:  2001-05       Impact factor: 9.139

Review 6.  Human T lymphotropic virus type-I and adult T-cell leukemia in Japan.

Authors:  Kazunari Yamaguchi; Toshiki Watanabe
Journal:  Int J Hematol       Date:  2002-08       Impact factor: 2.490

7.  Major depression and generalized anxiety disorder among human T-lymphotropic virus types I- and II-infected former blood donors.

Authors:  Anne M Guiltinan; Zhanna Kaidarova; Dee Behan; Cheryl Marosi; Sheila Hutching; Mandi Kaiser; Elane Moore; Deborah Devita; Edward L Murphy
Journal:  Transfusion       Date:  2012-05-03       Impact factor: 3.157

8.  HTLV-2 infection in injection drug users in King County, Washington.

Authors:  Joseph R Zunt; Ken Tapia; Hanne Thiede; Rong Lee; Holly Hagan
Journal:  Scand J Infect Dis       Date:  2006

9.  Molecular epidemiology of simian T-cell lymphotropic virus type 1 in wild and captive sooty mangabeys.

Authors:  Vicki L Traina-Dorge; Rebecca Lorino; Bobby J Gormus; Michael Metzger; Paul Telfer; David Richardson; David L Robertson; Preston A Marx; Cristian Apetrei
Journal:  J Virol       Date:  2005-02       Impact factor: 5.103

10.  Determinants of subject visit participation in a prospective cohort study of HTLV infection.

Authors:  Deborah A DeVita; Mary C White; Xin Zhao; Zhanna Kaidarova; Edward L Murphy
Journal:  BMC Med Res Methodol       Date:  2009-03-10       Impact factor: 4.615

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.